Carol Kim and Michael Spagnola, CDER Office of Generic Drugs, provides a general overview on the
review of a clinical endpoint bioequivalence study in ANDA applications. We want to provide helpful tips and practical examples of common deficiencies noted from the clinical reviewer’s perspective.
_______________________________
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.
Upcoming training and free continuing education credits: [ Ссылка ]
CDER SBIA 2017 Playlist: [ Ссылка ]
LinkedIn: [ Ссылка ]
Training resources: [ Ссылка ]
Twitter: [ Ссылка ]
CDER small business e-mail update subscription: [ Ссылка ]
Email: CDERSBIA@fda.hhs.gov
Phone: (301) 796-6707 I (866) 405-5367
